MEI Pharma Q4 Adj EPS $(1.51), Sales $1.46M Beat $930.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
MEI Pharma reported Q4 adjusted losses of $(1.51) per share and sales of $1.46 million, beating the analyst consensus estimate of $930.00 thousand by 56.67 percent. However, this represents an 87.23 percent decrease over sales of $11.41 million the same period last year.
September 26, 2023 | 8:47 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
MEI Pharma's Q4 results beat estimates but showed a significant YoY decrease in sales. The company also reported adjusted losses of $(1.51) per share.
While MEI Pharma beat the analyst consensus estimate for Q4 sales, the significant YoY decrease in sales and reported losses per share are likely to negatively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100